H.R. 8333 · 118TH CONGRESSHouse · Apr 16, 2026
BIOSECURE Act
Take Action
Introduced
House
Senate
Resolving Differences
President
Became Law
Summary
Summary being verified.
Summary being verified.
On Motion to Suspend the Rules and Pass, as Amended
On Motion to Suspend the Rules and Pass, as Amended
The House of Representatives passed H.R. 8333, known as the BIOSECURE Act, under a suspension of the rules which requires a two-thirds majority. The bill aims to protect U.S. national security by prohibiting federal agencies from contracting with or providing grants to specific biotechnology companies deemed to be controlled by foreign adversaries, particularly those based in China. It also prevents the government from doing business with entities that use equipment or services from these targeted firms. The vote saw strong bipartisan support, though the majority of the opposition came from the Democratic caucus. While 195 Republicans and 111 Democrats voted in favor of the measure, 79 Democrats and 2 Republicans voted against it. Supporters argue the bill is necessary to protect American genomic data and supply chains from foreign interference, while some critics expressed concerns regarding the potential impact on existing pharmaceutical research and development timelines. Because the bill passed the House, it now moves to the Senate for consideration. If the Senate passes the legislation and the President signs it into law, federal agencies and their contractors will have to begin a multi-year phase-out of their relationships with the restricted biotechnology providers.